# Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

> **NCT04471428** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 366 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Atezolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04471428
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2022-09-28
- **Final completion:** 2025-01-17
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471428, "Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04471428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*